GSWM
CNCR

Golden State Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Golden State Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-72
Closed -$2K – 1075
2019
Q1 		$2K Buy
+72
New +$1.51K ﹤0.01% 1011

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Golden State Wealth Management's CNCR Position: Q2 2019 in Review

Golden State Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2019, closing a stake of 72 shares — an estimated $2K sold.

Golden State Wealth Management first reported a position in CNCR in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 20 funds tracked by Wall St. Rank hold CNCR as of Q2 2019.

  • Golden State Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2019 after selling out during the quarter.
  • Golden State Wealth Management sold 72 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2019, an estimated $2K.
  • Golden State Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2019 and held it in 1 quarter.
  • Golden State Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $2K in Q1 2019.
  • 20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2019.

Based on Golden State Wealth Management's 13F filing for Q2 2019, filed 9 Aug 2019.